Innovent Biologics, Inc. (HKG:1801)
83.30
+4.85 (6.18%)
Mar 6, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 6,190 employees as of June 30, 2025. The number of employees increased by 531 or 9.38% since the number was reported on December 31, 2024.
Employees
6,190
Change
531
Growth
9.38%
Revenue / Employee
2.02M HKD
Profits / Employee
200.45K HKD
Market Cap
144.54B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6,190 | 531 | 9.38% |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 23,056 |
| WuXi Biologics | 12,552 |
| BeOne Medicines AG | 11,000 |
| 3SBio | 6,268 |
| Shanghai Henlius Biotech | 3,537 |
| Akeso | 3,529 |
| RemeGen | 3,070 |
| Shanghai Junshi Biosciences | 2,670 |
Innovent Biologics News
- 22 days ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer - PRNewsWire
- 25 days ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 26 days ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
- 26 days ago - Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology - PRNewsWire
- 5 weeks ago - Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma - PRNewsWire
- 2 months ago - Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration - PRNewsWire
- 2 months ago - China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval - PRNewsWire
- 3 months ago - Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody - PRNewsWire